• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.

作者信息

Docherty Kieran F, McMurray John J V

机构信息

BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

出版信息

Eur J Heart Fail. 2021 Jan;23(1):27-30. doi: 10.1002/ejhf.2075. Epub 2020 Dec 29.

DOI:10.1002/ejhf.2075
PMID:33283384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8048660/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1d/8048660/3b988187f771/EJHF-23-27-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1d/8048660/3b988187f771/EJHF-23-27-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc1d/8048660/3b988187f771/EJHF-23-27-g001.jpg

相似文献

1
SOLOIST-WHF and updated meta-analysis: sodium-glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure.SOLOIST-WHF研究及更新的荟萃分析：对于因心力衰竭加重而住院的患者，应起始使用钠-葡萄糖协同转运蛋白2抑制剂。
Eur J Heart Fail. 2021 Jan;23(1):27-30. doi: 10.1002/ejhf.2075. Epub 2020 Dec 29.
2
Use of sodium glucose co-transporter 2 inhibitors in acute heart failure: a practical guidance.钠-葡萄糖共转运蛋白 2 抑制剂在急性心力衰竭中的应用：实用指南。
ESC Heart Fail. 2022 Dec;9(6):4344-4347. doi: 10.1002/ehf2.14090. Epub 2022 Aug 25.
3
Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.对钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭的评论
Am J Cardiol. 2020 May 15;125(10):1602. doi: 10.1016/j.amjcard.2020.03.001. Epub 2020 Mar 5.
4
Meta-Analysis Evaluating the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction According to Baseline Anemia.根据基线贫血情况评估钠-葡萄糖协同转运蛋白2抑制剂对射血分数降低的心力衰竭患者心血管疗效的Meta分析
Am J Cardiol. 2022 Sep 15;179:111-114. doi: 10.1016/j.amjcard.2022.06.011. Epub 2022 Jul 22.
5
Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
Am J Cardiol. 2022 Jun 1;172:171-172. doi: 10.1016/j.amjcard.2022.03.010. Epub 2022 Apr 5.
6
Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors.
JACC Heart Fail. 2018 Jan;6(1):85. doi: 10.1016/j.jchf.2017.07.008.
7
Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.射血分数保留的心力衰竭中钠-葡萄糖协同转运蛋白2抑制剂：一项系统评价和荟萃分析。
Eur J Prev Cardiol. 2022 May 6;29(6):e227-e229. doi: 10.1093/eurjpc/zwab189.
8
Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.心力衰竭的治疗：钠-葡萄糖协同转运蛋白2抑制剂时代的曙光。
Eur Heart J. 2020 Sep 21;41(36):3379-3383. doi: 10.1093/eurheartj/ehaa810.
9
Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.心力衰竭的新热点：心力衰竭中的钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）
Arq Bras Cardiol. 2021 Feb;116(2):355-358. doi: 10.36660/abc.20210031.
10
Sodium-glucose co-transporter-2 inhibitors and protection from cardiovascular death: Is it all about heart failure?钠-葡萄糖协同转运蛋白2抑制剂与预防心血管死亡：这一切都与心力衰竭有关吗？
Diabetes Obes Metab. 2021 Sep;23(9):2194-2196. doi: 10.1111/dom.14444. Epub 2021 Jun 9.

引用本文的文献

1
Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failure.钠-葡萄糖协同转运蛋白2抑制剂对中国汉族慢性心力衰竭患者心血管结局和代谢事件的影响。
Diabetol Metab Syndr. 2024 Dec 18;16(1):299. doi: 10.1186/s13098-024-01553-z.
2
Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.索格列净与达格列净对改善糖尿病伴心力衰竭恶化患者结局的比较：每项结局的成本分析
Front Pharmacol. 2024 Apr 17;15:1373314. doi: 10.3389/fphar.2024.1373314. eCollection 2024.
3
Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights.

本文引用的文献

1
Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂与酮体生成：有利有弊。
Curr Diab Rep. 2020 Nov 23;20(12):74. doi: 10.1007/s11892-020-01359-z.
2
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
3
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry.
当前心力衰竭恶化的处理方法：病理生理学和分子学见解。
Int J Mol Sci. 2024 Jan 26;25(3):1574. doi: 10.3390/ijms25031574.
4
Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?心力衰竭的实用药物治疗：射血分数还重要吗？
J Cardiovasc Dev Dis. 2023 Mar 9;10(3):114. doi: 10.3390/jcdd10030114.
5
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?SGLT2 抑制剂：下一个重磅多效药物？
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.
6
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease.近期 2 型糖尿病的药理学选择及在心血管疾病中的协同机制
Int J Mol Sci. 2023 Jan 13;24(2):1646. doi: 10.3390/ijms24021646.
7
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects.在中国健康受试者中多次递增剂量后的索格列净的药代动力学、药效学、安全性和耐受性。
Drug Des Devel Ther. 2022 Sep 6;16:2967-2980. doi: 10.2147/DDDT.S372575. eCollection 2022.
8
Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂与 2 型糖尿病及其他心血管疾病危险因素患者心血管结局的相关性：一项荟萃分析。
JAMA Netw Open. 2022 Jan 4;5(1):e2142078. doi: 10.1001/jamanetworkopen.2021.42078.
9
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.钠-葡萄糖协同转运蛋白 2 抑制剂作为射血分数降低的心力衰竭患者的早期一线治疗药物。
Eur J Heart Fail. 2022 Mar;24(3):431-441. doi: 10.1002/ejhf.2397. Epub 2022 Jan 17.
10
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.钠-葡萄糖协同转运蛋白2抑制剂：心力衰竭治疗的新途径。
Korean Circ J. 2021 May;51(5):399-408. doi: 10.4070/kcj.2021.0070.
美国食品药品监督管理局达格列净标签在美国临床实践中对射血分数降低的心力衰竭患者的适用性：“遵循指南-心力衰竭（GWTG-HF）注册研究”
JAMA Cardiol. 2021 Mar 1;6(3):267-275. doi: 10.1001/jamacardio.2020.5864.
4
Diabetic ketoacidosis with SGLT2 inhibitors.伴有SGLT2抑制剂的糖尿病酮症酸中毒
BMJ. 2020 Nov 12;371:m4147. doi: 10.1136/bmj.m4147.
5
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
6
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
7
Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.达格列净治疗射血分数降低的心力衰竭的成本效益：DAPA-HF 的跨国卫生经济分析。
Eur J Heart Fail. 2020 Nov;22(11):2147-2156. doi: 10.1002/ejhf.1978. Epub 2020 Sep 15.
8
Do We Need Clinical Events Committees to Adjudicate End Points?我们是否需要临床事件委员会来判定终点？
Circ Heart Fail. 2020 Jul;13(7):e007209. doi: 10.1161/CIRCHEARTFAILURE.120.007209. Epub 2020 Jun 25.
9
Sotagliflozin: A Review in Type 1 Diabetes.索格列净：用于 1 型糖尿病的药物评价。
Drugs. 2019 Dec;79(18):1977-1987. doi: 10.1007/s40265-019-01230-w.
10
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.恩格列净对射血分数降低的慢性心力衰竭患者发病率和死亡率影响的评估：EMPEROR-Reduced 试验的原理和设计。
Eur J Heart Fail. 2019 Oct;21(10):1270-1278. doi: 10.1002/ejhf.1536. Epub 2019 Jul 16.